A. Burchardt

发表

Detection of an activated JAK3 variant and a Xq26.3 microdeletion causing loss of PHF6 and miR-424 expression in myelodysplastic syndromes by combined targeted next generation sequencing and SNP array analysis.

A. Rosenwald, F. Grimminger, A. Bräuninger, 2014, Pathology, research and practice.

Ongoing trials in low-grade lymphoma

A. Burchardt, 2011, Hematology reports.

Clinical characteristics and outcomes of invasive Lomentospora prolificans infections: Analysis of patients in the FungiScope® registry

M. Christner, L. Pagano, D. Seidel, 2020, Mycoses.

Aspergillus PCR-Based Investigation of Fresh Tissue and Effusion Samples in Patients with Suspected Invasive Aspergillosis Enhances Diagnostic Capabilities

C. Heussel, W. Hofmann, H. Wolf, 2013, Journal of Clinical Microbiology.

Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group

M. Labopin, C. Huber, A. Yaman, 2005, Bone Marrow Transplantation.

Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD.

R. Greil, K. Döhner, R. Schlenk, 2019, Blood.

Outcome of non-mold effective anti-fungal prophylaxis in patients at high-risk for invasive fungal infections after allogenic stem cell transplantation

R. Naumann, C. Trenker, A. Neubauer, 2019, Leukemia & lymphoma.

Voriconazole plus terbinafine combination antifungal therapy for invasive Lomentospora prolificans infections: analysis of 41 patients from the FungiScope® registry 2008-2019.

M. Christner, L. Pagano, D. Seidel, 2020, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia

K. Döhner, H. Döhner, V. Gaidzik, 2017, Leukemia.

Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN).

K. Strauch, C. Schade-Brittinger, T. Haferlach, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study.

A. Ganser, M. Stauch, W. Brugger, 2017 .

Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)

R. Greil, C. Buske, A. Hinke, 2019, Blood.

Bendamustin-Rituximab Induction Followed by Observation or Rituximab Maintenance for Newly Diagnosed Patients with Waldenström's Macroglobulinemia: Results From a Prospective, Randomized, Multicenter Study (StiL NHL 7–2008 –MAINTAIN-; ClinicalTrials.gov Identifier: NCT00877214).

R. Greil, U. Jaeger, C. Buske, 2012 .

Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with marginal zone lymphoma (MZL): Results of a prospective, randomized, multicenter phase 2 study (the StiL NHL7-2008 MAINTAIN trial).

R. Greil, A. Ganser, A. Hinke, 2018 .

Four Versus Two Years of Rituximab Maintenance (R-maintenance) Following Bendamustine Plus Rituximab (B-R): Initial Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN study)

R. Greil, C. Buske, A. Hinke, 2017 .

Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD.

R. Greil, K. Döhner, R. Schlenk, 2019, Blood.